Carregant...
Combined inhibition of MEK and Plk1 has synergistic anti-tumor activity in NRAS mutant melanoma
About one third of cancers harbor activating mutations in rat sarcoma viral oncogene homolog (RAS) oncogenes. In melanoma, aberrant neuroblastoma-RAS (NRAS) signaling fuels tumor progression in about 20% of patients. Current therapeutics for NRAS driven malignancies barely impact overall survival. T...
Guardat en:
| Publicat a: | J Invest Dermatol |
|---|---|
| Autors principals: | , , , , , , , , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
2015
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4567913/ https://ncbi.nlm.nih.gov/pubmed/26016894 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/jid.2015.198 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|